Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Refractory malignant ascites is a common complication in tumor patients. To date, chemotherapy and paracentesis represent the most widely used methods to relieve the symptoms. Lately, intraperitoneal therapy with catumaxomab, a trifunctional hybrid antibody, has been introduced for the treatment of malignant ascites, and its utility has been demonstrated in patients with distinct abdominal malignancies. We report the first case of successful catumaxomab treatment of malignant ascites in a patient with advanced carcinoma of the urinary bladder and liver cirrhosis. Although at admission a large volume paracentesis was needed every other day, paracentesis was no longer necessary after catumaxomab therapy. Catumaxomab might represent a safe treatment option for malignant ascites in the course of metastatic urothelial carcinoma, also in the setting of liver cirrhosis.